TAT-GluN2BCTM is a membrane-permeable peptide that selectively targets active DAPK1 (Death-associated protein kinase 1) for lysosomal degradation, protecting neurons against oxidative stress and NMDAR-mediated excitotoxicity, making it valuable for neuroprotection research studies [1].

TAT-GluN2BCTM (200 µM) reduces DAPK1 levels in NMDA-treated primary neuronal cultures in a time-dependent manner over 0.5, 2, and 4 hours [1].

Administration of TAT-GluN2BCTM (10 mg/kg; i.v.; single) resulted in a significant decrease in the levels of active DAPK1 in the ischemic hemisphere of the rat brain [1]. TAT-GluN2BCTM demonstrated substantial neuroprotective effects in the cortex and striatum of rats [1]. Furthermore, TAT-GluN2BCTM was able to specifically reduce the activity of the active (but not inactive) form of DAPK1 [1].